Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
15.9M
-
Number of holders
-
7
-
Total 13F shares, excl. options
-
56.9K
-
Shares change
-
+56.9K
-
Total reported value, excl. options
-
$158K
-
Value change
-
+$158K
-
Number of buys
-
7
-
Price
-
$2.78
Significant Holders of ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) as of Q3 2023
8 filings reported holding ADIL - ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share as of Q3 2023.
ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) has 7 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.9K shares
of 15.9M outstanding shares and own 0.36% of the company stock.
Largest 8 shareholders include Manchester Capital Management LLC (48.1K shares), BlackRock Inc. (7.64K shares), OSAIC HOLDINGS, INC. (615 shares), UBS Group AG (546 shares), Abound Wealth Management (27 shares), MORGAN STANLEY (21 shares), Qube Research & Technologies Ltd (8 shares), and WELLS FARGO & COMPANY/MN (8 shares).
This table shows the top 7 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.